GlaxoSmithKline’s in-development shingles vaccine successfully staved off the virus in a massive Phase III study–and, in contrast with its top competitor, the shot’s effects didn’t wane among elderly patients.

…read more

Source: GlaxoSmithKline’s shingles vaccine gets a leg up on Merck’s rival with a PhIII win


0 No comments